PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma-Reference-Cited by-同舟云学术

PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma

Published:2021-10-25 Issue: Volume: Page:
ISSN:1536-1632
Container-title:Molecular Imaging and Biology
language:en
Short-container-title:Mol Imaging Biol

Author:

Bellavia Michael C.,Nyiranshuti Lea,Latoche Joseph D.,Ho Khanh-Van,Fecek Ronald J.,Taylor Jennifer L.,Day Kathryn E.,Nigam Shubhanchi,Pun Michael,Gallazzi Fabio,Edinger Robert S.,Storkus Walter J.,Patel Ravi B.^ORCID,Anderson Carolyn J.

Funder

national institutes of health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11307-021-01666-1.pdf

Reference45 articles.

1. Larkin J et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535–1546

2. Hodi FS et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11):1558–1568

3. Postow MA et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017

4. Ascierto PA et al (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10:85–85

5. Flaherty KT et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potent and Selective Oxidatively Labile Ether‐Based Prodrugs through Late‐Stage Boronate Incorporation;Angewandte Chemie;2024-09-03

2. Potent and Selective Oxidatively Labile Ether‐Based Prodrugs through Late‐Stage Boronate Incorporation;Angewandte Chemie International Edition;2024-09-02

3. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen;Nuclear Medicine and Biology;2024-09

4. Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications;Biomedicines;2024-01-30

5. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists;Frontiers in Immunology;2024-01-18